BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lorenzo GD, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, Stefano AD, Esposito V, Placido SD, Montesarchio V. Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. World J Gastroenterol 2007; 13(48): 6553-6557 [PMID: 18161926 DOI: 10.3748/wjg.v13.i48.6553] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L. A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs 2008;26:381-6. [PMID: 18305899 DOI: 10.1007/s10637-008-9124-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wu D, Vogus D, Krishnan V, Broto M, Pusuluri A, Zhao Z, Kapate N, Mitragotri S. Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant Liposomes. Pharmaceutics 2021;13:107. [PMID: 33467652 DOI: 10.3390/pharmaceutics13010107] [Reference Citation Analysis]